FORM D

UNITED STA

Washington, D



OMB APPROVAL

FORM D

NOTICE OF SALE OF SECURITIES
PURSUANT TO REGULATION D,
SECTION 4(6), AND/OR
IFORM LIMITED OFFERING EXEMPTION

SEC USE ONLY						
Prefix		Serial				
DAT	E RECEIV	ÆD				

					-	
Name of Offering (check if this is an amend	dment and nam Warrants	e has changed, and	indicate chang	ge.)	7/2-11	127-82
Filing Under (Check box(es) that apply): Type of Filing:	□Rule 504	□Rule : ☑New Filing	505	⊠Rule 506	Section 4	(6) ULOE
	A. BA	SIC IDENTIFICA	ATION DATA	\		
1. Enter the information requested about the	issuer				· · · · · · · · · · · · · · · · · · ·	
Name of Issuer (check if this is an amendment Lipid Sciences, Inc.	ent and name l	nas changed, and in	dicate change.)		
Address of Executive Offices 7068 Koll Center Parkway, Suite 401, Pleas		nd Street, City, Star 566-3111	te, Zip Code)		none Number (Incl 249-4000	uding Area Code)
Address of Principal Business Operations (No from Executive Offices)	imber, Street,	City, State, Zip Coo	le) (if different		none Number (Incl	uding Area Code)
Brief Description of Business Research and development					Trasclipcon of co each acid Haveto	
Type of Business Organization			,'			TURASON
⊠ corporation	☐ limited	partnership, already	formed		other (please s	PECITHOMSON FINANCIAL
☐business trust	limited	partnership, to be fo	ormed			- PHANAON II
		<u>Month</u>	<u>Y</u> 6	<u>ear</u>		
Actual or Estimated Date of Incorporation or 0	Organization:	May	99)		☐ Estimated
Jurisdiction of Incorporation or Organization:	•	-letter U.S. Postal S nada, FN for other t			DE	:

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C 77d(6).

When to File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

Where to File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State:

This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

ATTENTION

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

			
· ·	A. BASIC ID	ENTIFICATION DATA	
Enter the information reque Each promoter of the is	ested for the following: suer, if the issuer has been organized	within the past five years	<u></u>
			or more of a class of equity securities of
•	and director of corporate issuers and o	of corporate general and managing partne	ers of partnership issuers: and
	ging partner of partnership issuers.		
Check Box(es)	Promoter	Beneficial Owner	⊠Executive Officer
that Apply:	⊠Director	General and/or Managing Partner	
Full Name (Last name first, if in	ndividual)		
Radlick, Phil C.			
7068 Koll Center Parkway, St	(Number and Street, City, State, Zip uite 401, Pleasanton, CA 94566-311	1	
Check Box(es)	Promoter	Beneficial Owner	Executive Officer
that Apply: Full Name (Last name first, if in	⊠Director ndividual)	General and/or Managing Partner	
Cham, Bill E.	(Number and Street, City, State, Zip	Coda)	
	uite 401, Pleasanton, CA 94566-311		•
Check Box(es)	Promoter	⊠Beneficial Owner	⊠Executive Officer
that Apply:	⊠Director	General and/or Managing Partner	7 3-
Full Name (Last name first, if in Marlett, Christopher	ndividual) stem to the loss to	• • • • • • • • • • • • • • • • • • • •	under traggioten in die in die inder der Werder der Weiter
7068 Koll Center Parkway, St	(Number and Street, City, State, Zip aite 401, Pleasanton, CA 94566-311)	754	en i Seneral en
Check Box(es) that Apply:	☐Promoter ☐Director	Beneficial Owner General and/or Managing Partner	Endow(%) Executive Officer (#1997) Lop(y (1997)
Full Name (Last name first, if in Roubin, Gary S.		¥° s ⊃ģ	Transplante en en en Ericke († 1967). Karl Kantog S
350 E. 79th Street, 23A, New	(Number and Street, City, State, Zip York, NY 10021		ora et Walderga hage
Check Box(es)	Promoter	Beneficial Owner	☑Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if in Gardiner, Sandra	idividual)		
Business or Residence Address	(Number and Street, City, State, Zip nite 401, Pleasanton, CA 94566-3111		
Check Box(es)	Promoter	⊠Beneficial Owner	Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if in MDB Capital Group IV, LLC			
Business or Residence Address 100 Wilshire Blvd., 17th Floor	(Number and Street, City, State, Zip., Santa Monica, CA 90401	Code)	
Check Box(es)	Promoter	Beneficial Owner	☐Executive Officer
that Apply:	Director	General and/or Managing Partner	
Full Name (Last name first, if in Aruba International Pty Ltd.			· · · · · · · · · · · · · · · · · · ·
	(Number and Street, City, State, Zip site 401, Pleasanton, CA 94566-3111		
Check Box(es)	Promoter	Beneficial Owner	Executive Officer
that Apply: Full Name (Last name first, if in	Director	General and/or Managing Partner	
THE PARTY OF THE P	ru:viudži i		

Business or Residence Address (Number and Street, City, State, Zip Code)

				В.	INFORMA	TION ABO	OUT OFFE	RING				
1. H	as the issuer se	old, or does	the issuer in	-			stors in this of 2, if filing t	_		. Yes 🗌	No ⊠	
2. W	hat is the min	imum inves	tment that w	rill be accept	ed from any	individual?)	•••••••••		. \$1	<u> </u>	
3. De	oes the offerin	g permit joi	int ownershi	p of a single	unit?	•••••	•••••			. Yes 🏻	No 🔲	
re: ag	nter the inform muneration fo ent of a broke rsons to be lis	r solicitation r or dealer r	n of purchas egistered wi	ers in conne th the SEC	ction with s and/or with	ales of secur a state or sta	rities in the o ites, list the	offering. If	a person to broker or o	be listed is a dealer. If mo	n associate re than five	d person or
Full N	ame (Last nar	ne first, if in	idividual)							, , , , , , , , , , , , , , , , , , , ,	_	
Busine	ess or Residen	ce Address	(Number an	d Street, Cit	y, State, Zip	Code)			-			
Name	of Associated	Broker or I	Dealer				<u>-</u>					
	in Which Pers									All Stat		
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]		[ME]	[MD]	[MA]	ε [MI]	[MN]	- [MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]		[NC]	[ND]	[OH]		[OR]	
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[wv]	[SC[WA]	°C[WY]	[PR]
Fuil N	ame (Last nan	ne first, it in	idividual)	er de la companya de			الم العاملية		\$	्री-क्रास्त्रक र ौ		VIII TV
Busine	ess or Residen	ce Address	(Number an	d Street, Cit	y, State, Zip	Code)				Marine .	1 - 22.51 (
Name	of Associated	Broker or I	Dealer								-	·
	in Which Pers											
(Check	c "All States" [AK]	or check ind [AZ]	dividual Stat [AR]	es) [CA]	[CO]	[CT]	[DE]	[DC]	[FL]	All State [GA]	es 🔲 [HI]	[ID]
[IL]	[IN]	[A2]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT]	[NE]	[NV]	[NH]	[NJ]	[NM]	[NY]	[NC]	[ND]	[OH]	[OK]	[OR]	[PA]
[RI]	[SC]	[SD]	[TN]	[TX]	[UT]	[VT]	[VA]	[VA]	[WV]	[WI]	[WY]	[PR]
Full N	ame (Last nan	ne first, if in	dividual)									
Busine	ss or Residen	ce Address ((Number and	1 Street, City	y, State, Zip	Code)	/ ***					
Name	of Associated	Broker or D)ealer		<u>-</u> -	··				 -,		
States	in Which Pers	on Listed H	las Solicited	or Intends t	o Solicit Pu	rchasers	· · · · · · · · · · · · · · · · · · ·			·	·	
•	"All States"			•			••••••	•••••		All State		
[AL]	[AK]	[AZ]	[AR]	[CA]	[CO]	[CT]	[DE]	[DC]	[FL]	[GA]	[HI]	[ID]
[IL]	[IN]	[IA]	[KS]	[KY]	[LA]	[ME]	[MD]	[MA]	[MI]	[MN]	[MS]	[MO]
[MT] [RI]	[NE] (SC)	[NV] [SD]	[NH] [TN]	[NJ] [TX]	[NM] [UT]	[NY] [VT]	[NC] [VA]	[ND] [VA]	[OH] [WV]	[OK] [WI]	(OR) (WY)	[PA] [PR]

	C. OFFERING PRICE, NUMBER OF INVESTORS, EXPE	NSES AND USE OF PROC	EEDS
1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box \(\square\$ and indicate in the columns below the amounts of the securities offering for exchange and already exchanged.		
	Type of Security Debt Equity	Aggregate Offering Price \$0- \$	Amount Already Sold \$0 \$3,000,000
	· ·	33,000,000	3 <u>3,000,000</u>
	☐ Common ☐ Preferred	e 0	
	Convertible Securities (including warrants)	\$	\$
	Partnership Interests	\$ <u>-0-</u> \$ -0-	\$ \$
	Other (Specify)	· ———————	·
	Total	\$ <u>3,000,000</u>	\$ <u>3,000,000</u>
	Answer also in Appendix, Column 3, if filing under ULOE.		i
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."		
			Aggregate Dollar Amount
		Number Investors	of Purchases
	Accredited Investors	2	\$ <u>3,000,000</u>
	Non-accredited Investors		\$
	Total (for filings under Rule 504 only)	<u>-0-</u>	\$ <u>-0-</u>
	Answer also in Appendix, Column 4, if filing under ULOE	·	anneagh a Air Cruit an thoras a com
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C - Question 1.	Cin.	res forces of the provided to the first of forces of the first of the
	Type of Offering	Type of Security	Dollar Amount Sold
	Rule 505		\$
	Regulation A		s
	Rule 504		s
	Total		s;
			:
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees		\$.
	Printing and Engraving Costs	ā	\$
	Legal Fees	\boxtimes	\$10,000
	Accounting Fees	ā	s
	Engineering Fees		S
	Sales Commissions (specify finders' fees separately)		\$
	Other Expenses (Identify)		S
	Total	ā	S10,000_
	b. Enter the difference between the aggregate offering price given in response to Part C – Question I and total expenses furnished in response to Part C - Question 4.a. This difference is the "adjusted gross proceeds to the issuer"		\$ 2,990,000

. .

			;	
C. OFFERING PRICE, NUMBER OF INVESTO	ORS, EXPENSES	AND USE OF P	PROCEEDS	
5. Indicate below the amount of the adjusted gross proceeds to the issuer us proposed to be used for each of the purposes shown. If the amount for ar purpose is not known, furnish an estimate and check the box to the left of estimate. The total of the payments listed must equal the adjusted gross p to the issuer set forth in response to Part C - Question 4.b above.	ny f the proceeds			
	•	yments to Officer ectors, & Affilia	,	
Salaries and fees		□ \$	Payments To	Others
Purchase of real estate		□ s	□ s	_
Purchase, rental or leasing and installation of machinery and equipment		□ s	□ s	_
Construction or leasing of plant buildings and facilities.		□ \$	☐ \$	
Acquisition of other businesses (including the value of securities involved in offering that may be used in exchange for the assets or securities of another is pursuant to a merger)	ssuer	□ s	∏s :	
Repayment of indebtedness				
Working capital		□ s	⊠ \$2,990,0	000
Other (specify):	-			
		□ s	□ s	
Column Totals		□ s	<u> </u>	000
Total Payments Listed (column totals added)			⊠ \$ <u>2,990,000</u>	
	•	•		
D. FEDERAL SI	IGNATURE	A 12		:
		f this notice is fi	led under Rule 505, the fo	llowing*
The issuer had duly caused this notice to be signed by the undersigned duly as signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to	uthorized person. I ities and Exchange paragraph (b)(2) o	Commission, up	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc.	uthorized person. It ities and Exchange paragraph (b)(2) of Signature	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc.	uthorized person. It ities and Exchange paragraph (b)(2) of Signature	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	uthorized person. I ities and Exchange paragraph (b)(2) of Signature Title of Signer (P	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type) Sandra Gardiner	tities and Exchange paragraph (b)(2) of Signature Title of Signer (Proceedings of Secretary	Commission, up of Rule 502.	on written request of its st	
The issuer had duly caused this notice to be signed by the undersigned duly a signature constitutes an undertaking by the issuer to furnish to the U.S. Securinformation furnished by the issuer to any non-accredited investor pursuant to Issuer (Print or Type) Lipid Sciences, Inc. Name of Signer (Print or Type)	tities and Exchange paragraph (b)(2) of Signature Title of Signer (Proceedings of Secretary	Commission, up of Rule 502.	on written request of its st Date March 21, 2001	

.....

.. . _

_...

	E. STATE SIGNATURE	
1.	İs any party described in 17 CFR 230.262 presently subject to any of the disqualification provisions of such rule?	
	See Appendix, Column 5, for state response.	
2.	The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which the notice is filed, a notice on Form D (17 CFR 239.500) at such times as required by state law.	
3.	The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished by the issuer to offerees.	
4.	The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the Uniform limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the availability of this exemption has the burden of establishing that these conditions have been satisfied.	•
	e issuer has read this notification and knows the contents to be true and has duly caused this notice to be signed on its behalf by the undersigned y authorized person.	
Iss	Lipid Sciences, Inc. Signature Date March 2, 2001	
Na	ne of Signer (Print or Type) Sandra Gardiner Title of Signer (Print or Type) Secretary	

Instruction:

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX 2 3 4 Disqualification under State ULOE Type of security and aggregate (if yes, attach offering price explanation of Type of investor and amount purchased in State (Part C-Item 2) Intend to sell to non-accredited offered in State waiver granted investors in State (Part B-Item 1) (Part C-Item 1) (Part E-Item 1) Numb Number of er of Warrants Accredited Non-State Yes No Investors Amount Accre Amount Yes No dited Invest ors ALΑK AZAR 0 CA X \$3,000,000 2 \$3,000,000 0 X CO CT DE DC FL GA НІ ID ILINΙA KS ΚY LA ME MD MA MI

MN	-							:	
MS								:	
МО									
MT									
NE								·	
NV									
NH									
NJ									
NM									
NY									
NC									
ND								:	
ОН			:			1.2	J		i
OK			·		Ę				
OR	e interestable of the entire section of the	en e	ه ود تها در د استود ماه بادسته در دین از د	e e e e e e e e e e e e e e e e e e e	1		a ser er ser er e		eg . neggs
PA					* ;	1 100 cm	<u>.</u>	,	. 0
RI	· · · · · · · · · · · · · · · · · · ·					57		,	
sc								•	
SD									
TN									
TX						<u> </u>			
UΤ						ļ		:	
VT									
VA								· · · · · ·	
WA									
wv						-			
						1	1		l
WI						 			
WI WY									

.